Content available at: https://www.ipinnovative.com/open-access-journals

Indian Journal of Microbiology Research

Journal homepage: www.ijmronline.org

Review Article

Regenerative medicine in India: A landscape review of scientific progress, regulatory pathways, and future opportunities

Rakesh Pandit[1]*, Ashutosh Shukla[2], Nikita Paliya[3]

[1]Indus University, Ahmedabad, Gujarat, India
[2]Dept. of Health Sciences, Indus University, Ahmedabad, Gujarat, India
[3]Integrated Institute of Medical and Health Sciences, New Delhi, India

Abstract

India stands at a unique and pivotal crossroads in the global landscape of regenerative medicine. With its vast patient population, skilled scientific workforce, and burgeoning biotechnology sector, the nation holds immense potential to become a leader in this revolutionary field. This comprehensive review synthesizes the current state of regenerative medicine in India, examining the three core pillars that will define its future: scientific progress, regulatory pathways, and persistent challenges. We analyze the significant advancements in stem cell research, particularly with Mesenchymal stem cells (MSCs) across various clinical applications including orthopedics, cardiology, and dermatology and also discuss the emergence of other advanced cell-derived therapies. We then delineate the evolution of India's regulatory framework, from its early, ambiguous phase to the current dual-pronged structure governed by the National guidelines for stem cell research (NGSCR) and the New drugs and clinical trials rules (NDCTR, 2019). This framework critically distinguishes between minimally manipulated cells for autologous use and substantially manipulated cell-based products classified as "drugs." However, significant hurdles remain, including the persistent ethical quandary of "stem cell tourism," a critical deficit in GMP-certified manufacturing facilities, and the "valley of death" in funding that stalls the translation of promising research into clinical therapies. The high cost and affordability of these novel therapies also pose a significant challenge to widespread access. This review concludes that for India to realize its potential, a concerted effort is required from policymakers, scientists, clinicians, and industry stakeholders to strengthen regulatory enforcement, build indigenous manufacturing capacity, foster an ecosystem for innovation streamline commercialization processes, and ultimately ensure that advanced therapies are safe, effective, and accessible to its population.

Keywords: Regenerative medicine, Stem cell therapy, Regulatory framework, Translational research, CAR-T therapy, Good manufacturing practice, Stem cell tourism, Cell-derived therapies, Cost and affordability.

Received: 29-07-2025; **Accepted:** 13-09-2025; **Available Online**: 20-09-2025

1. Introduction

Regenerative medicine, a multidisciplinary field that aims to repair, replace, or regenerate damaged human cells, tissues, and organs, represents a paradigm shift in modern healthcare.[1] By harnessing the body's innate healing capabilities through tools like stem cell therapy, tissue engineering, and gene editing, it offers the potential to move beyond mere disease management to definitive cures for conditions currently considered intractable.[2] Globally, the field has evolved from a nascent scientific concept into a dynamic industry with an expanding pipeline of clinical trials and commercial therapies for diseases ranging from osteoarthritis to myocardial infarction and neurodegenerative disorders.[3]

India, with its large burden of chronic and degenerative diseases, a skilled and cost-effective pool of scientists and clinicians, and a robust pharmaceutical industry, is uniquely positioned to play a pivotal role in this global revolution.[4] The landscape of regenerative medicine in India, however, is a study in contrasts. It is a domain of immense promise and

*Corresponding author: Rakesh Pandit
Email: rakesh.its@gmail.com

https://doi.org/10.18231/j.ijmr.12618.1931623825

significant paradox, where cutting-edge research in premier institutions coexists with the proliferation of unproven therapies, and where a sophisticated regulatory framework is challenged by systemic issues of enforcement and ethical ambiguity.[5]

The impetus for navigating these challenges is not just clinical but also economic. The global regenerative medicine market is projected to grow exponentially, with some market analyses forecasting its value to exceed USD 100 billion by 2030.[6] For India, successfully capitalizing on even a fraction of this market could lead to significant economic growth, job creation in the high-tech biotech sector, and a reduction in the economic burden of chronic diseases. This dual potential—to both heal patients and build a globally competitive industry—makes the strategic development of this field a national priority.

This dichotomy presents both a massive opportunity and a formidable challenge. To harness the potential of regenerative medicine for both public health improvement and economic growth, a clear-eyed understanding of the current landscape is essential. This review aims to provide a comprehensive overview by examining three critical aspects: the current state of scientific progress and clinical applications including cell-derived therapies, within India; the complex and evolving regulatory pathways governing research and commercialization; and the key challenges and future opportunities that will shape the trajectory of the field in the coming decade, with particular attention to cost and affordability issues.

2. The Landscape of Scientific Progress in India

Scientific research in regenerative medicine in India has gained significant momentum, primarily concentrated in government-funded research centers, premier academic institutions, and a growing number of private startups and hospitals.[4,7]

2.1. The workhorse of Indian research: Mesenchymal stem cells (MSCs) and other cell-derived therapies

A dominant trend in Indian stem cell research is the focus on Mesenchymal stem cells (MSCs). Derived from accessible sources like bone marrow, adipose tissue, and umbilical cord blood, MSCs are attractive for several reasons. Their multipotent capacity allows them to differentiate into various cell types like bone, cartilage, and fat.[8] Crucially, they possess powerful immunomodulatory properties, enabling their use in allogeneic settings with a lower risk of rejection.[3] Their perceived safety profile and relative ease of isolation have made them the most widely studied cell type in Indian clinical trials, forming the backbone of translational research efforts.[5]

Beyond whole cell transplantation, significant work is also being done on cell-derived therapies, which involve using components or secretions from cells rather than the cells themselves. These include exosomes, secretomes, and growth factors, which offer advantages like easier storage, reduced immunogenicity, and simpler administration.[9,10] For instance, studies are exploring MSC-derived exosomes for their regenerative potential in conditions like myocardial infarction and chronic wounds, offering a cell-free approach to harness the therapeutic benefits of MSCs.[11]

2.2. Key clinical applications under investigation and leading research institutes

While research spans numerous areas, several clinical applications have emerged as frontrunners in the Indian context:

1. Orthopedics: This is arguably one of the most clinically advanced areas. MSC-based therapies are being widely investigated and offered for the treatment of osteoarthritis, avascular necrosis, and cartilage defects.[12] Institutions like the Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, and various orthopedic specialty hospitals are at the forefront of clinical trials using autologous MSCs for joint repair and cartilage regeneration.[13]
2. Dermatology: A notable area of clinical success has been in the treatment of stable vitiligo. The transplantation of autologous, non-cultured epidermal cell suspensions and melanocyte-keratinocyte suspensions has shown encouraging results in achieving stable repigmentation.[14] AIIMS, New Delhi, has published extensively on these techniques, developing standardized protocols.
3. Cardiology: Stem cell-based therapies, particularly using autologous bone marrow-derived stem cells, are being explored for cardiac regeneration post-myocardial infarction.[15] Research groups at institutions like the Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), Thiruvananthapuram, are actively involved in preclinical and early-phase clinical studies to understand optimal cell types, delivery methods, and paracrine effects that contribute to improved cardiac function.[16]
4. Neurology: Early to mid-stage clinical research is active in treating neurological conditions such as spinal cord injury and Parkinson's disease. Institutes like the National Centre for Biological Sciences (NCBS), Bangalore, and various neuroscience centers are investigating the potential of stem cells to promote neural repair and improve functional outcomes.[17]
5. Other promising areas: Early to mid-stage clinical research is active in treating critical limb ischemia to prevent amputation, chronic liver diseases, and diabetes, often involving MSCs or other cell-derived products.[5]

3. The Evolving Regulatory Pathway: A Dual-Track System

India's regulatory journey for regenerative medicine reflects a maturation from a largely unregulated space to a more structured, risk-based framework.[18] Governance is primarily split between two key bodies: the Indian Council of Medical Research (ICMR) for overseeing research ethics and the Central Drugs Standard Control Organisation (CDSCO) for regulating products intended for commercial use.[19]

3.1. The foundation: National guidelines for stem cell research (NGSCR)

First issued in 2007 and periodically updated (most recently in 2017), the NGSCR, formulated by the ICMR and Department of Biotechnology (DBT), provides the ethical and scientific guardrails for all stem cell research in India.[1,18] It created a clear distinction between permissible, restricted, and prohibited areas of research and established a national-level apex committee and institutional committees to oversee all projects, bringing a much-needed layer of oversight. The guidelines are crucial for ensuring responsible scientific conduct and protecting research participants.

3.2. The core regulatory distinction: Process vs. product

The cornerstone of India's regulatory approach, solidified in the New Drugs and Clinical Trials Rules (NDCTR) of 2019, is the classification of Stem Cell and Cell-Based Products (SCCPs) based on their degree of manipulation.[20,21]

1. Minimally manipulated cells: When autologous cells are minimally manipulated and used for a homologous function, the procedure is generally considered a medical practice. This means the regulation falls under the purview of the treating physician and their institutional ethics committee, adhering to the principles outlined in the NGSCR. Examples include the direct grafting of uncultured skin cells for vitiligo or the immediate re-infusion of bone marrow concentrate for orthopedic conditions.
2. Substantially manipulated cells (Classified as "Drugs"): If cells are substantially manipulated (e.g., expanded in culture, genetically engineered combined with non-cellular components) or used for a non-homologous function, the resulting product is classified as a "drug." This classification is critical, as it brings the product under the stringent regulatory purview of the CDSCO. Such products must undergo the formal four-phase clinical trial process demonstrating safety and efficacy, and receive marketing authorization before they can be sold commercially.[19,21] This also applies to allogeneic cell products, which inherently involve substantial manipulation for donor screening, processing, and often expansion.

This dual-track system wisely separates innovative medical procedures from the industrial manufacturing of cell-based drugs, providing distinct pathways for each.



Figure 1: The dual-track regulatory pathway for cell-based products in India. 4. Key challenges and hurdles

Despite a robust scientific base and a clear regulatory framework on paper, the path to widespread clinical adoption in India is fraught with significant challenges.

4. Regulatory and Ethical Challenges

1. The scourge of "Stem Cell Tourism": India has long been a global hotspot for "stem cell tourism," where private, unregulated clinics market unproven and often dangerous therapies directly to desperate patients.[22] This practice not only poses a grave risk to patient safety but also severely damages the reputation of legitimate scientific research in the country.[5]
2. Gaps in regulatory enforcement: While the NDCTR 2019 provides a clear definition of what constitutes a cell-based "drug," the enforcement against clinics that flout these rules by marketing substantially manipulated cells as a "practice" remains a major challenge.[1,18] This often stems from a lack of public awareness, insufficient regulatory personnel, and the intricate legal battle required to shut down such operations.
3. Ethical oversight for minimal manipulation: Even for minimally manipulated procedures, ensuring consistent ethical oversight across all private clinics and smaller hospitals, which may lack sophisticated Institutional Ethics Committees, is a persistent concern.

5. Scientific and Manufacturing Hurdles

The GMP manufacturing bottleneck: The translation of cell therapies from the lab to the clinic requires scalable, reproducible manufacturing in state-of-the-art Good Manufacturing Practice (GMP) certified facilities. India faces a critical shortage of such facilities, creating a major bottleneck that prevents promising academic research from ever reaching late-stage clinical trials and commercial production.[4,23] Most existing facilities are either small-scale academic units or focus on conventional pharmaceutical production.

Prohibitive costs and quality control: The cost of GMP-grade reagents, specialized equipment, and maintaining the stringent quality control and assurance (QA/QC) systems required for cell therapies is extremely high.[24] This directly impacts the final cost of the therapy, making it potentially unaffordable for the majority of the Indian population. Developing cost-effective, indigenous solutions for these components is crucial.

Lack of standardization: A lack of nationally standardized protocols for cell isolation, characterization, cryopreservation, and expansion makes it difficult to compare results across different studies and ensure the consistency and potency of cell-based products.[20] This fragmentation hinders multi-center trials and broader clinical adoption.

6. Commercialization and Funding Gaps

1. The translational "Valley of Death": A significant funding gap exists between early-stage, government-funded academic research and the capital-intensive late-stage clinical trials and commercialization phases.[4,25] Public funding mechanisms are robust for basic research but often fall short for the expensive, high-risk translational work needed to bring a product to market**.**
2. Immature venture capital ecosystem: While growing, the domestic venture capital ecosystem for high-risk, long-gestation biotech ventures like regenerative medicine is still less mature compared to Western markets. Investors often shy away from the substantial upfront investment and long timelines associated with cell and gene therapy development.
3. Uncertain reimbursement pathways and affordability: The absence of clear health insurance and reimbursement policies for these expensive, novel therapies is a major barrier to market access and patient uptake.[24] Even if therapies are approved, their high cost puts them out of reach for most patients, necessitating innovative pricing models, government subsidies, or inclusion in public health schemes.
4. Complex commercialization process: Navigating the commercialization process from R&D to market approval involves intricate steps, including intellectual property protection, technology transfer, scale-up manufacturing, and market access strategies. Indian startups often struggle with these aspects due to limited experience and resources.

Table 1: Summary of key challenges impeding regenerative medicine in India

Category	Specific Challenge	Primary Impact
Regulatory & Ethical	"Stem Cell Tourism"	Damages patient safety and field reputation.
	Gaps in Enforcement	Undermines legitimate research and development, patient risk
Scientific & Manufacturing	GMP Manufacturing Bottleneck	Stalls translation from research to clinic, limited scale
	Prohibitive Costs & Quality Control	Limits scalability and affordability.
Commercialization & Funding	Translational "Valley of Death"	Promising research fails to reach late-stage trials.
	Uncertain Reimbursement Pathways	Major barrier to market access and patient uptake.
	Complex Commercialization Process	Challenges for startups in navigating market entry.

7. Future Opportunities

The future of regenerative medicine in India is bright, provided the current challenges can be navigated with strategic foresight.

1. Leveraging India's intrinsic strengths: India's large, genetically diverse patient population is a significant asset for conducting large-scale, cost-effective clinical trials, potentially accelerating drug development. The country's skilled scientific and medical workforce, coupled with lower operational costs compared to Western nations, provides the essential human capital for innovation and cost-efficient research.
2. Focus on "frugal innovation" and affordability: There is a massive opportunity for Indian companies to become world leaders in developing high-quality, cost-effective regenerative therapies. By innovating on manufacturing processes, sourcing local materials, and optimizing supply chains, India can make advanced therapies accessible not only to its own population but also to other emerging economies, creating a distinct global niche.

3. Strengthening public-private partnerships (PPPs): Collaborative models between government research institutions (e.g., ICMR, DBT), private industry, and clinical centers can help bridge the funding gap and accelerate the translation of research from the lab to the clinic. Such partnerships can also facilitate knowledge transfer and resource sharing.
4. Investing in infrastructure: A national mission-mode project to build more shared, multi-institutional GMP manufacturing facilities, potentially supported by government grants and industry investment, could be a game-changer for academics and startups. This would reduce the individual burden of establishing such expensive infrastructure.
5. Streamlining commercialization: Establishing dedicated platforms or incubators that guide regenerative medicine startups through the complex commercialization process—from IP protection and regulatory submissions to market strategy and funding—can accelerate product launch and adoption.

Beyond MSCs, India is beginning to make strides in more advanced therapeutic modalities. A landmark development has been the recent approval by the CDSCO of the first indigenously developed CAR-T cell therapy for cancer by ImmunoACT, a testament to the country's growing capabilities in complex cell and gene therapy manufacturing.[26] While still nascent, research in gene editing technologies like CRISPR-Cas9 for treating genetic disorders such as sickle cell anemia and thalassemia is also gaining traction in premier Indian institutions, including the Centre for Cellular and molecular biology (CCMB), Hyderabad.[27] These advancements signal India's potential to move beyond foundational stem cell therapies and become a contributor to the most cutting-edge areas of regenerative medicine.

8. Conclusion

Regenerative medicine in India is a field of profound promise and significant paradox. The nation has demonstrated considerable scientific capability and has established a sophisticated, risk-based regulatory framework that is, in principle, aligned with global standards. However, to translate this promise into tangible clinical and economic benefits, India must now focus on the difficult task of execution. This requires a concerted, multi-stakeholder effort to strengthen regulatory enforcement against unproven therapies, build indigenous GMP manufacturing capacity, de-risk investment in translational research, create clear and affordable reimbursement pathways, and streamline the commercialization process. If these challenges can be met, India is well-positioned to emerge as a global leader in delivering the next generation of affordable and accessible regenerative therapies.

9. Source of Funding

None.

10. Conflict of Interest

None.

11. Acknowledgments

The authors wish to acknowledge the use of AI language models, specifically Gemini, for assistance in refining language, improving clarity, and restructuring certain sections of the manuscript. The authors confirm that all content has been thoroughly reviewed, verified, and approved for accuracy and originality.

References

1. Mittal S. Stem cell research: the India perspective. *Perspect Clin Res*. 2013;4(1):105–7.
2. Mao AS, Mooney DJ. Regenerative medicine: current therapies and future directions. *Proc Natl Acad Sci U S A*. 2015;112(47):14452–9.
3. Bauer G, Abou-El-Enein M, Kent A, Poole B, Forte M. The path to successful commercialization of cell and gene therapies: empowering patient advocates. *Cytotherapy*. 2017;19(2):293–8.
4. Tiwari SS, Raman S, Martin P. Regenerative medicine in India: trends and challenges in innovation and regulation. *Regen Med*. 2017;12(7):875–85.
5. Grand View Research. *Regenerative Medicine Market Size, Share & Trends Analysis Report*. Grand View Research; 2023. Accessed September 19, 2025. https://www.grandviewresearch.com/industry-analysis/regenerative-medicine-market.
6. Gupta DR, Singh S. Stem cells: current applications and future prospects. *Int J Med Sci*. 2023;76(1):2–6.
7. Lahiry S, Choudhury S, Sinha R, Chatterjee S. The National Guidelines for Stem Cell Research (2017): what academicians need to know? *Perspect Clin Res*. 2019;10(4):148–54.
8. Coelho A, Alvites RD, Branquinho MV, Guerreiro SG, Maurício AC. Mesenchymal stem cells (MSCs) as a potential therapeutic strategy in COVID-19 patients: literature research. *Front Cell Dev Biol*. 2020;8:602647.
9. Muthu S, Bapat A, Jain R, Jeyaraman N, Jeyaraman M. Exosomal therapy-a new frontier in regenerative medicine. *Stem Cell Investig*. 2021;8:7.
10. Sreenivas A, Jha D. Cell-Free Therapies: Revolutionizing the Approach to Cellular Treatments. In: *Advances in Regenerative Medicine and Tissue Engineering*. London: IntechOpen; 2025. https://doi.org/10.5772/intechopen.1008700.
11. Allan D, Tieu A, Lalu M, Burger D. Mesenchymal stromal cell-derived extracellular vesicles for regenerative therapy and immune modulation: progress and challenges toward clinical application. *Stem Cells Transl Med*. 2020;9(1):39–46.
12. Schmitt A, van Griensven M, Imhoff AB, Buchmann S. Application of stem cells in orthopedics. *Stem Cells Int*. 2012:394962.
13. Malige A, Gates C, Cook JL. Mesenchymal stem cells in orthopaedics: a systematic review of applications to practice. *J Orthop*. 2024;58:1–9.
14. Esquivel D, Mishra R, Srivastava A. Stem cell therapy offers a possible safe and promising alternative approach for treating vitiligo: a review. *Curr Pharm Des*. 2020;26(37):4815–21.
15. Yan W, Xia Y, Zhao H, Xu X, Ma X, Tao L. Stem cell-based therapy in cardiac repair after myocardial infarction: promise, challenges, and future directions. *J Mol Cell Cardiol*. 2024;188:1–14.
16. Arnous S, Mozid A, Martin J, Mathur A. Bone marrow mononuclear cells and acute myocardial infarction. *Stem Cell Res Ther*. 2012;3(1):2.
17. Agosti E, Zeppieri M, Pagnoni A, Fontanella MM, Fiorindi A, Ius T, et al. Current status and future perspectives on stem cell transplantation for spinal cord injury. *World J Transplant*. 2024;14(1):89674.

18. Cherukuri VP, Ch SB, Golla M, Konagala SGS, Penugonda VLDSS, Addanki S. Regulatory Framework for Regenerative Medicine in India. *Int J Drug Reg Affairs*. 2021;9(3):25-1.
19. Khabade AM, Agarwal SS, Mahajan HB, Mandlik SK. Navigating regulatory requirements for stem cells therapy- a review on regulations of US, European Union, Japan and India. *Int J Drug Reg Affairs*. 2024;12(3):66–81.
20. Government of India, Ministry of Health and Family Welfare. New Drugs and Clinical Trials Rules [Internet]. New Delhi: The Ministry; 2019 [cited 2025 Sep 12]. Available from: https://cdsco.gov.in/opencms/opencms/system/modules/CDSCO.WEB/elements/download_file_division.jsp?num_id=OTk1Ng==.
21. Aly RM. Current state of stem cell-based therapies: an overview. *Stem Cell Investig*. 2020;7:8.
22. Einsiedel EF, Adamson H. Stem cell tourism and future stem cell tourists: policy and ethical implications. *Dev World Bioeth*. 2012;12(1):35–44.
23. Deguchi K, Zambaiti E, De Coppi P. Regenerative medicine: current research and perspective in pediatric surgery. *Pediatr Surg Int*. 2023;39(1):167.
24. Laurencin CT, McClinton A. Regenerative cell-based therapies: cutting edge, bleeding edge, and off the edge. *Regen Eng Transl Med*. 2020;6(1):78–89.
25. Cherukuri VP, Ch SB, Golla M, Konagala SGS, Penugonda VLDSS, Addanki S. Regulatory Framework for Regenerative Medicine in India. *Int J Drug Reg Affairs*. 2021;9(3):25–31.
26. Press Information Bureau, Government of India. *CDSCO approves India's first indigenously developed CAR T-cell therapy for commercial use* [Internet]. New Delhi: The Bureau; 2023 Oct [cited 2025 Sep 12]. Available from: https://www.pib.gov.in/PressReleasePage.aspx?PRID=2017169.
27. Li R, Wang Q, She K, Lu F, Yang Y. CRISPR/Cas systems usher in a new era of disease treatment and diagnosis. *Mol Biomed*. 2022;3(1):31.

Cite this article: Pandit R, Shukla A, Paliya N. Regenerative medicine in India: A landscape review of scientific progress, regulatory pathways, and future opportunities. *Indian J Microbiol Res*. 2025;12(3):317–322.